RxAlly and Shenandoah University team up to increase pneumocaccol vaccine uptake rates

The pharmacy alliance RxAlly recently announced that it has entered into a partnership with Shenandoah University's pharmacology school to collaborate on a pneumococcal-focused grant project

RxAlly, a first-of-its kind alliance of more than 22,000 U.S. pharmacies, said that the partnership received the grant from the biopharmaceutical company Pfizer. It will be used to enable pharmacy faculty members to assist local pharmacists implement a pneumococcal immunization program.

The program, known as "Improving Patient Immunization Rates through Optimizing Pharmacy's Role in Providing Immunization Services," is working towards increasing pneumococcal vaccination rates among adults over age 65 and at-risk patients with comorbid conditions.

Kerr Drug, a regional community pharmacy chain based in North Carolina, will play a major role in the initiative along with an experienced team of pharmacy educators, the American Pharmacists Association immunization trainers, an accredited medical education company and RealCME, an outcomes analytics company. Kerr Drug is a member of RxAlly.

"We couldn't be more honored and excited to work with Shenandoah University on this important public health initiative," RxAlly CEO Bruce Roberts said. "Studies show the proven value of pharmacists in increasing immunization rates and this will continue to create awareness of how pharmacy can and does play a major role in improving health outcomes and reducing health care costs in our communities."